D-0069-2021 Class II Terminated

Recalled by Teva Pharmaceuticals USA — Parsippany, NJ

FDA drug recall D-0069-2021 was initiated by Teva Pharmaceuticals USA on Oct 28, 2020 and is designated Class II. Reason for recall: Failed Dissolution Specifications: Out-of-specification dissolution results were obtained during stability testing. The recall status is terminated (terminated Aug 26, 2021). Affected quantity: 133,829 bottles.

Recall details

Product Type
Drugs
Report Date
Nov 18, 2020
Initiation Date
Oct 28, 2020
Termination Date
Aug 26, 2021
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
133,829 bottles

Product description

Mesalamine Delayed-Release Tablets, USP 1.2 gram, 120 tablets per bottle, Rx Only, Manufactured by: Actavis Laboratories, FL, Inc., Fort Lauderdale, FL 33314, Distributed by: Actavis Pharma Inc., Parsippany, NJ 07054, NDC 0591-2245-22.

Reason for recall

Failed Dissolution Specifications: Out-of-specification dissolution results were obtained during stability testing.

Distribution pattern

Nationwide in the U.S. and PR

Code information

Lot #s: 1342498A, Exp. 12/2020; 1342499A, Exp. 01/2021; 1354638A, Exp. 03/2021; 1354639A, 1358274A, 1358448A, 1364618A, 1369884A, Exp. 05/2021; 1366195A, 1369885A, 1373570A, Exp. 06/2021; 1373571A, Exp. 07/2021; 1388571A, Exp. 01/2022; 1395725A, 1396585A, 1397550A, 1399389A, Exp. 04/2022; 1403885A, 1403886A, Exp. 06/2022.

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0069-2021
openFDA file date
Nov 16, 2026
Loaded by RegDataLab
Nov 17, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0069-2021. Report a data issue: hello@regdatalab.com.